• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    GREENBUTTS APPPOINTS FORMER BIG TOBACCO EXECUTIVE AS CHIEF STRATEGY OFFICER

    6/22/22 2:34:00 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTI alert in real time by email

    SAN DIEGO, Calif., June 22, 2022 /PRNewswire/ - Greenbutts, LLC (the "Company" or "Greenbutts") is pleased to announce the appointment of Luis Sanches as the Company's Chief Strategy Officer effective immediately.

    Greenbutts' Chief Strategy Officer, Luis Sanches (CNW Group/GreenButts)

    Luis is a Senior Corporate Executive with more than 30 years of international, cross functional and cross-cultural experience responsible for managing business teams, supporting growth, and leading transformations across multiple geographies such as Australasia, North and South America, and Europe.

    He was previously the Senior Vice President of R&D for Reynolds American Inc., an American tobacco company and subsidiary of British American Tobacco (NYSE:BTI); the second-largest tobacco company in the United States that generated north of $35 billion revenue for 2021. His corporate tenure under British American Tobacco spanned 31 years in total, including the position of Group Head of Product Development in the United Kingdom and Vice President of Kentucky BioProcessing KBP - a world leader in developing and employing cGMP processes to manufacture recombinant proteins using novel plant-based technology. He successfully led the development of novelty scientific knowledge and multi-category consumer lead product innovations.

    "Never before in history have industry and humanity at large shared such a commitment to understand and urgently address matters that negatively impact the sustainability of our planet and, ultimately, our lives. Greenbutts is pioneering solutions that will allow business partners to focus on their growth strategy and deliver their product innovation pipeline while materially advancing their ESG agendas," said Mr. Sanches. "I am proud to join the Greenbutts team and am committed with them "to give every fiber of our being" to offering meaningful sustainable solutions to our partners." Sanches continued.

    "We are delighted to have an executive of Mr. Sanches' calibre and industry presence, knowledge, and experience join our already accomplished team," said Tadas Lisauskas, Founder and CEO of Greenbutts. 

    "For the past 11 years, Greenbutts™️ has been focused on developing a viable alternative to cellulose acetate filters for the global cigarette industry, through extensive R&D and cross-continental partners. While we have had much success in achieving this goal; patenting our technology, continuously adding intellectual property to our portfolio, and validating business cases on a global stage, the addition of Luis Sanches to the team is an opportunity to re-introduce ourselves to the global cigarette industry and assist in their efforts to make the inevitable transition to a zero-plastic alternative as seamless as possible," added Tadas.

    Luis will oversee the company's global expansion strategy regarding material and filter production in every region which Greenbutts serves customers. In addition, Mr. Sanches will work on optimizing our filter manufacturing process to meet the regulatory needs and specifications of each of our customers.

    Mr. Sanches' expertise of the industry along with his long-standing relationships he has built during his three decades in big tobacco will assist Greenbutts in developing these markets and supporting ESG commitments of global tobacco partners.

    About Greenbutts™️

    Since 2010, Greenbutts has worked with R&D institutions, international tobacco companies, and industry experts to develop biodegradable filter technology – trademarked as a "Greenbutt". The Company has developed and patented a "zero-plastic" filter, made without any synthetic materials or plasticizers, 100% biodegradable and water dispersing which meets certain industry criteria. The proprietary Greenbutts filter is designed to reduce the significant environmental impact caused by plastic cigarette filter pollution. Over 6 trillion are discarded every year making single-use filters the most littered plastic item in the world. With over a decade of R&D and strong intellectual property, Greenbutts offers the $1 Trillion global tobacco industry a seamless transition to zero-plastic filters while meeting the new global single-use plastic (SUP) legislation initiatives.

    FORWARD-LOOKING INFORMATION

    This release includes forward-looking information within the meaning of Canadian securities laws and forward-looking statements within the meaning of U.S. securities laws (collectively, "forward-looking information"). Statements containing the words "believe", "expect", "intend", "should", "seek", "anticipate", "will", "positioned", "project", "risk", "plan", "may", "could", "estimate", or, in each case, their negative and words of similar meaning, are intended to identify forward-looking information. Forward-looking information in this release, which includes but is not limited to, trends in the disposable cigarette butts industry and market, including any potential future growth thereof, Greenbutts' plans for research and development and any potential commercialization of products, any potential results from clinical studies that may be undertaken by Greenbutts, any statements as to the efficacy of products that Greenbutts may develop, any future submission by Greenbutts of regulatory approval applications, any future receipt by Greenbutts of regulatory approval for any products that it may develop, any future receipt by Greenbutts of patents that have been applied for or may be applied for in respect of its technologies, the success of Greenbutts' existing and future business strategies and objectives and implementation, including any resulting benefits to Greenbutts' operations or financial and non-financial performance as a result of such strategies and objectives and implementation, completion of financing, and the use of proceeds of a financing, is subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. Such risks and uncertainties included but are not limited to, risks related to completion of a financing; dilutive effect of an offering and future offerings; competition from other competitor companies; violations of laws and regulations could result in repercussions; regulatory or political change; requirement of commercial scale and quality manufactured product supply; negative operating cash flow and going concern; limited operating history; requirement for additional capital to continue to develop business and realize on objectives; lack of product revenue; unfavourable publicity or consumer perception; reliance on the capabilities and experience of key executives and management; risk of product liability claims; COVID-19; litigation; conflicts of interest; ability to protect intellectual property; changes in patent law; requirement to share intellectual property to service providers; general economic, market and business conditions; and other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended.

    These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. In addition, even if the outcome of the plans and events described herein are consistent with the forward-looking information contained in this release, those results or developments may not be indicative of results or developments in subsequent periods. Forward-looking information contained in this release is based on the beliefs and expectations of Greenbutts' management, which Greenbutts believes are reasonable as of the current date, and are subject to significant business, social, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors. Many assumptions are based on factors and events that are not within the control of Greenbutts and actual future results may differ materially from current expectations. Except as required by applicable law, Greenbutts assumes no obligation to update or revise any forward-looking information in this release to reflect new events or circumstances.

    www.greenbutts.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/greenbutts-apppoints-former-big-tobacco-executive-as-chief-strategy-officer-301573411.html

    SOURCE GreenButts

    Get the next $BTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTI

    DatePrice TargetRatingAnalyst
    4/30/2025Buy
    BofA Securities
    1/27/2025Neutral → Buy
    UBS
    10/3/2024$33.00Overweight → Underweight
    Morgan Stanley
    1/23/2024Neutral
    UBS
    11/1/2023$38.00Overweight
    Morgan Stanley
    9/25/2023Buy
    Citigroup
    9/1/2023Buy → Hold
    Argus
    3/13/2023Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Bt De Investments Inc.

      3 - British American Tobacco p.l.c. (0001303523) (Reporting)

      11/23/22 4:29:54 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities resumed coverage on British American Tobacco

      BofA Securities resumed coverage of British American Tobacco with a rating of Buy

      4/30/25 9:01:21 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • British American Tobacco upgraded by UBS

      UBS upgraded British American Tobacco from Neutral to Buy

      1/27/25 7:35:54 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • British American Tobacco downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded British American Tobacco from Overweight to Underweight and set a new price target of $33.00

      10/3/24 7:24:54 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

      SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

      2/9/24 6:03:23 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

      SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

      2/9/24 5:46:32 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

      SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

      1/26/24 4:56:06 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Charlotte's Web Reports 2024 First Quarter Financial Results

      LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile

      5/8/24 7:07:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • British American Tobacco p.l.c investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla

      1/24/24 6:21:08 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Organigram Announces C$124.6 Million Investment from BAT and Creation of "Jupiter" Strategic Investment Pool

      Organigram and BAT deepen partnership through C$124.6 million investment with 38.7 million shares to be issued over three tranches Organigram to use C$83.1 million of the investment to create "Jupiter," a strategic investment pool designed to expand Organigram's geographic footprint and capitalize on emerging growth opportunities C$41.5 million of the investment will be used for general corporate purposes Investment enhances strategic Product Development Collaboration between BAT and Organigram, which focuses on cutting-edge R&D and product innovation BAT to increase voting Common Share ownership position to 30% and overall equity interest to 45% (including non-voting Class A P

      11/6/23 6:00:00 AM ET
      $BTI
      $OGI
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BTI
    SEC Filings

    See more
    • SEC Form 6-K filed by British American Tobacco Industries p.l.c.

      6-K - British American Tobacco p.l.c. (0001303523) (Filer)

      5/9/25 11:07:44 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by British American Tobacco Industries p.l.c.

      6-K - British American Tobacco p.l.c. (0001303523) (Filer)

      5/6/25 12:33:01 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by British American Tobacco Industries p.l.c.

      6-K - British American Tobacco p.l.c. (0001303523) (Filer)

      5/1/25 7:49:52 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Financials

    Live finance-specific insights

    See more
    • Charlotte's Web Reports 2024 First Quarter Financial Results

      LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile

      5/8/24 7:07:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Charlotte's Web Reports 2023 Second Quarter Financial Results

      Encouraging CBD regulatory progress in CongressNet revenue of $16.0M vs. $18.9M YoYCash increased to $61.7M LOUISVILLE, Colo., Aug. 10, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full spectrum hemp extract wellness products, today reported financial results for the second quarter ended June 30, 2023.  Regulatory Update During the second quarter, the U.S. Food and Drug Administration ("FDA") committed to "work at speed" with Congress to resolve a regulatory pathway for hemp-derived CBD.

      8/10/23 7:33:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Charlotte's Web Reports 2023 First Quarter Financial Results

      Net cash of $61MNet revenue of $17M decreased 12.1% YoY14% YoY reduction in operating expenses LOUISVILLE, Colo., May 12, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2023. "In the first quarter, we maintained prudent cost controls to balance softness in the CBD category due to the unregulated environment. We successfully reduced operating expenses by 14% on a year-over-ye

      5/12/23 7:05:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTI
    Leadership Updates

    Live Leadership Updates

    See more
    • British American Tobacco p.l.c investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2024 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla

      1/24/24 6:21:08 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Charlotte's Web Announces Appointment of Bill Morachnick as Chief Executive Officer

      Provides Update on Majority Voting Policy Process LOUISVILLE, Colo., Sept. 13, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") is pleased to announce the appointment of William (Bill) Morachnick who has joined the Company as its Chief Executive Officer. Mr. Morachnick has also been appointed to the Company's Board of Directors as a non-independent director. He replaces CEO Jacques Tortoroli who has elected to resign from his roles at Charlotte's Web.  CWEB) (OTCQX:CWBHF):. The World's Most Trusted Hemp Extract and Official CBD of Major League Baseball (MLB). (C

      9/13/23 7:07:00 AM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care
    • GREENBUTTS APPPOINTS FORMER BIG TOBACCO EXECUTIVE AS CHIEF STRATEGY OFFICER

      SAN DIEGO, Calif., June 22, 2022 /PRNewswire/ - Greenbutts, LLC (the "Company" or "Greenbutts") is pleased to announce the appointment of Luis Sanches as the Company's Chief Strategy Officer effective immediately. Luis is a Senior Corporate Executive with more than 30 years of international, cross functional and cross-cultural experience responsible for managing business teams, supporting growth, and leading transformations across multiple geographies such as Australasia, North and South America, and Europe. He was previously the Senior Vice President of R&D for Reynolds Ameri

      6/22/22 2:34:00 PM ET
      $BTI
      Medicinal Chemicals and Botanical Products
      Health Care